• 1
    Brodie MJ, Kwan MD. Staged approach to epilepsy management. Neurology 2002;58: S28.
  • 2
    Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004;45(suppl. 6):1318.
  • 3
    Taylor CP, Vartanian MG, Yuen P, et al. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labelled by tritiated gabapentin. Epilepsy Res 1993;14: 1115.
  • 4
    Dooley DJ, Donovan CM, Meder WP, et al. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002;45(3):17190.
  • 5
    Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42(2):22936.
  • 6
    Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent nodulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295: 108693.
  • 7
    Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280: 107110.
  • 8
    Bryans JS, Wustrow DJ. 3-Substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999;19: 14977.
  • 9
    Taylor CP, Vartanian MG. Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models. Epilepsia 1997;38(suppl. 8):8.
  • 10
    Williamson J, Lothman CTE, Bertran E. Comparison of S(+)-3 isobutyl GABA and gabapentin against kindled hippocampal seizures. Epilepsia 1997;38(suppl. 8):29.
  • 11
    Ben-Menachem E, Kugler AR. Pregabalin and epilepsy. In: ShorvonS, PerrucaE, FishD, DodsonE, eds. Treatment of epilepsy. 2nd ed. Oxford : Blackwell Publishing Ltd 2004, pp. 46999.
  • 12
    Ben-Menachem E, Kugler AR. Pregabalin. In: LevyRH, MattsonRH, MeldrumBS, et al., eds. Antiepileptic drugs. 5th ed. Philadelphia : Lippincott Williams & Wilkins, 2002 pp. 9015.
  • 13
    Bockbrader HN, Hunt T, Strand J, et al. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two phase 1 studies. Neurology 2000;54(suppl. 3):421.
  • 14
    Kugler AR, Robbins JL, Strand JC, et al. Pregabalin overview: a novel CNS-active compound with anticonvulsant activity. Poster presented at AES, Seattle, December 2002.
  • 15
    Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005;46: 140713.
  • 16
    Bockbrader HN, Burger PJ, Kugler AR, et al. Population pharmacokinetic (PK) analyses of commonly prescribed antiepileptic drugs (AEDs) coadministered with pregabalin (PGB) in adult patients with refractory partial seizures. Epilepsia 2001;42(suppl. 7):84.
  • 17
    French JA, Kugler AR, Robbins JL, et al. Dose–response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60: 16317.
  • 18
    Arroyo S, Anhut H, Kugler AR, et al., and the pregabalin 1008–011 International Study Group. Pregabalin add-on treatment: a randomized double-blind placebo-controlled dose–response study in adults with partial seizures. Epilepsia 2004;45: 2027.
  • 19
    Beydoun A, Uthman BM, Kugler AR, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005;64: 475480.
  • 20
    Miller R, Frame B, Corrigan B, et al. Exposure-response analysis of pregabalin add-on treatment of patients with refractory seizures. Clin Pharmacol Ther 2003;73: 491505.
  • 21
    Ferrendelli JA. Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia 2001;42(suppl. 4):2830.
  • 22
    Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures: from the Commission on Classification and Terminology of the International League against Epilepsy. Epilepsia 1981;22: 489501.
  • 23
    Department of Health and Human Services. Coding symbols for a thesaurus of adverse event reaction terms (COSTART). 4th ed. Rockville , MD : Department of Health and Human Services, US Food and Drug Administration (FDA) , 1996.
  • 24
    Mohanraj R, Brodie MJ. Measuring the efficacy of antiepileptic drugs. Seizure 2003;12: 41343.
  • 25
    Cramer JA, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999;40: 590600.